G ranzymes (Gzms)/perforin-mediated cytolysis is the major pathway for killer lymphocytes to eradicate pathogens and tumor cells. GzmK and GzmA are closely linked together on the same chromosome both in mice and humans (1, 2) . They are the only two tryptases among all of the Gzms (3). GzmA-deficient CTLs still contain 20% tryptase activity, and their cytolytic activity is just slightly reduced (4) . GzmK might therefore be a potent Gzm to rescue the GzmA activity. GzmK expresses at high levels in CD56 high NK cells, memory CD8 + T cells, and CD56 + T cells (5) . A recent study showed the levels of circulating GzmK are notably elevated in virus-infected patients (6) , suggesting that GzmK may play an important role in NK/ CTL-mediated virus clearance. We recently demonstrated that human GzmK induces rapid caspase-independent cell death with rapid externalization of phosphatidylserine, nuclear morphological changes, and ssDNA nicks (7) . After loading into target cells, GzmK targets the SET complex, resulting in the degradation of selected components, freeing the NM23H1 DNase and leading to ssDNA nicks, which is reminiscent of the dead features of GzmA. We found that GzmK can target the GzmA-associated SET complex and cleave the substrates of GzmA in the SET complex, including SET, Ape1, and HMGB2 (7, 8) . GzmK can also induce rapid generation of reactive oxygen species (ROS) and collapse of the mitochondrial inner membrane potential (9) . Cytochrome c (cyt c) is released from the mitochondrial outer membrane to the cytosol through a Bid-dependent way. However, GzmA induces a rapid increase in ROS and mitochondrial transmembrane potential loss through a Bid-independent way (10) . GzmK cleaves Ape1 and wrecks its redox function. Ape1 cleavage accelerates intracellular ROS accumulation and cell death (8) . We recently demonstrated that the tumor suppressor p53 is a specific substrate for GzmK (11) . GzmK cleaves p53 at Lys 24 and Lys 305 to generate three cleavage fragments that harbor strong proapoptotic activities to sensitize target cells to GzmK-mediated cytotoxicity. However, the mechanisms of the GzmK-mediated death pathway are still unclear.
The endoplasmic reticulum (ER) is a major organelle for protein synthesis, folding, and assembly in the secretory pathway. In fact, 30% of newly synthesized proteins in a cell are needed to be rapidly degraded because of improper protein folding (12) . Newly synthesized proteins in the ER of eukaryotic cells are subjected to rigorous quality control, which consists of a sophisticated protein proofreading and elimination mechanism. A coupled process termed the ER-associated degradation (ERAD) removes defective and misfolded proteins remaining in the ER to the 26S proteasome for degradation (13) . Accumulation of misfolded proteins, mutations affecting folding machinery, viral infection, nutrient deprivation, and disruption of calcium levels will increase the burden on the ER, thus causing an ER stress (14) . Cell death will initiate if an ER stress is not immediately relieved.
Valosin-containing protein (VCP) is a member of the type II ATPases associated with a variety of activities (AAA) ATPases. VCP has two ATPase activity domains named D1 and D2 (15) . VCP is a highly evolutionarily conserved protein (16, 17) . As an ATPase, VCP catalyzes ATP hydrolysis to generate energy and uses the energy to perform physiological functions in cells. VCP is a ubiquitous and abundant protein and plays important roles in cellular biological functions. VCP can form a complex with the Ufd1-Npl4 heterodimer and participate in the ERAD pathway to degrade misfolded proteins that are usually ubiquitinated for recognition and degradation (18) (19) (20) . In this study, we identified VCP what to our knowledge is a new substrate of GzmK by affinity chromatography and coimmunoprecipitation assay. GzmK cleaves VCP at residue Arg 713 in the D2 domain and abrogates its ATPase activity. GzmK can target other ERAD complex components, Ufd1 and Npl4, to destroy the ERAD pathway for misfolded protein degradation leading to ubiquitinated protein accumulation, which induces an ER stress leading to cell death.
Materials and Methods
Cell lines, Abs, and reagents Cells were grown in RPMI 1640 (Jurkat) and DMEM (HeLa) supplemented with 10% FCS, 50 mM 2-ME, 100 U/ml penicillin, and 100 mg/ml streptomycin. Commercial Abs were rabbit antisera against NM23H1 (Santa Cruz Biotechnology, Santa Cruz, CA), mouse mAbs against VCP for immunoblotting (BD Pharmingen, San Diego, CA), ubiquitin (Cell Signaling Technology, Beverly, MA), b-actin (BD Pharmingen), goat antisera against Ufd1 (Santa Cruz Biotechnology), HRP-conjugated sheep antimouse IgG, HRP-conjugated sheep anti-rabbit IgG, and HRP-conjugated rabbit anti-goat IgG (Santa Cruz Biotechnology). Anti-VCPAb for immunoprecipitation was a gift of Y. Ye (National Institutes of Health, Bethesda, MD); anti-Npl4 Ab was a gift of O. Stemmann (Max-Planck-Institute of Biochemistry, Martinsried, Germany). Mouse mAb against human GzmK was generated through hybridoma screening in our laboratory. This Ab is specific for GzmK and has no cross-reactivity with other Gzms. Rabbit SET antisera were generated, as described (7) . Reagents include Affi-gel 10 resin 
Plasmids and recombinant protein expression
The plasmids of GzmK and inactive S-AGzmK were constructed and expressed, as described (7) . Active GzmA was expressed in Escherichia coli and purified as GzmK. Active GzmB, GzmM, and GzmH were expressed in E. coli and purified from inclusion bodies, as described (21) . The construct of rVCP was a gift of T. Rapoport (Harvard Medical School, Boston, MA). rVCP was expressed in JM109 cells and purified sequentially over Novagen (Madison, WI) nickel column. The short hairpin RNA (shRNA) sequence targeting VCP is as follows: 59-GATCCCCG-TAGGGTATGATGACATTGTTCAAGAGACAATGTCATCATACCCTA-CTTTTTA-39 and 59-AGCTTAAAAAGTAGGGTATGATGACATTGTCT-CTTGAACAATGTCATCATACCCTACGGG-39. The VCP shRNA was subcloned in the pSUPER vector. The pcDNA3.1-VCP plasmid was a gift of T. Rapoport. HeLa cells were transfected by using Lipofectamin 2000 (Invitrogen), as described by the manufacturer. Empty vector-transfected cells were used as a control. The pEF-Bcl-2 or pEF vector (a gift of A. Strasser, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia) was transfected for Bcl-2 overexpression.
Affinity chromatography with S-AGzmK
Purified S-AGzmK (1 mg) was coupled to 0.5 ml Affi-Gel 10 (Bio-Rad) to generate an affinity column. Cytoplasmic extracts prepared from 5 3 10 8 HeLa cells treated with Nonidet P-40 lysis buffer (0.5% Nonidet P-40/25 mM KCl/5 mM MgCl 2 /1 mM PMSF/10 mM Tris-HCl [pH 7.6]) were applied to the column and eluted with gradient NaCl concentrations. The naked resin was used as a negative column control. Fractions were analyzed by SDS-PAGE and followed by silver staining. Protein bands at 97 and 37 kDa were subjected to tryptic digestion and identified by mass spectrometry.
Coimmunoprecipitation and immunoblotting
Abs were preincubated with protein A/G Sepharose (Pharmacia, Peapack, NJ) for 1 h at 4˚C. We washed Ab-coated beads twice in PBS buffer before adding them to recombinant proteins (50 mg/ml) or cytosolic lysates (5 3 10 6 cell equivalents in 20 ml Nonidet P-40 lysis buffer) that had been preincubated for 2 h at 4˚C with 50 mg/ml S-AGzmK. After overnight shaking at 4˚C, the beads were washed extensively in 1% Nonidet P-40 lysis buffer containing 150 mM NaCl and resolved by SDS-PAGE. The proteins were transferred to nitrocellulose membranes before probing with the indicated Abs.
Preparation of lymphokine-activated killer cells and lymphokine-activated killer cell-mediated cytolysis assay Loading GzmK with Ad/perforin/SLO HeLa or Jurkat cells were washed three times in PBS and resuspended in the loading buffer. Cells (2 3 10 5 ) in 50 ml loading buffer were incubated at 37˚C for the indicated times with different concentrations of GzmK, S-AGzmK, and an optimal dose of Ad, perforin, or SLO, as described before (7, 22) .
Cleavage assay
Cell lysates prepared from HeLa cells were treated with 0.5% Nonidet P-40 lysis buffer. Cell lysates (2 3 10 5 cell equivalents) or 1 mM rVCP was incubated with the indicated doses of GzmK or S-AGzmK or indicated does of GzmA, B, M, or H for the indicated times in 20 ml cleavage buffer (50 mM Tris-HCl [pH 7.5], 1 mM CaCl 2 , 1 mM MgCl 2 ). For in vivo cleavage assay, cells loaded with GzmK/Ad were lysed in 0.5% Nonidet P-40 lysis buffer. The reaction samples were terminated in 53 SDS loading buffer and probed by immunoblotting.
Enzymatic activity assays
Enzymatic activities were detected by cleavage of synthetic substrates. The substrates were as follows: Ac-YRFK-pNA (GzmK), Suc-VANR-pNA (GzmA), Z-IETD-AFC (GzmB), Suc-FLF-pNA (GzmH), and Suc-AAPLpNA (GzmM). Their activities were measured, as described (21) .
ATPase activity assay
ATP hydrolysis was measured directly by the conversion of ATP to ADP. Release of inorganic phosphate (Pi) was estimated, as described (23) . Briefly, rVCP was incubated with 1 mM ATP at 37˚C for 30 min in 100 ml buffer containing 10 mM HEPES-KOH (pH 7.4), 5 mM MgCl 2 , and 120 mM KCl. Inhibition by GzmK was performed with 1.5 mM rVCP, 1 mM ATP, and various amounts of GzmK. Reactions were stopped by addition of 200 ml 1% SDS. Samples (0.1 ml) were added to 0.7 ml ascorbatemolybdate reagent, which consists of 1 part 10% ascorbic and 6 parts 0.42% (w/v) ammonium molybdate in 1 N H 2 SO 4 . Tubes were incubated at 45˚C for 20 min, and absorbance was determined at 820 nm.
Intracellular ubiquitinated protein assay
For the analysis of intracellular ubiquitinated protein, HeLa cells (2 3 10 5 ) were treated with GzmK, GzmA, or GzmB plus Ad for the indicated times at 37˚C in loading buffer. The reaction samples were terminated in 53 SDS loading buffer, resolved on SDS-PAGE, and detected by immunoblotting using a ubiquitin Ab. Ubiquitinated proteins were analyzed by fluorescence microscopy. Briefly, Jurkat cells were treated with the indicated concentrations of GzmK plus Ad for the indicated times, and then plated on polyLys-coated slides. After being fixed with 4% paraformaldehyde for 20 min at room temperature and permeabilized with 0.05% Triton X-100 for another 5 min, cells were incubated at room temperature for 1 h with 5 mg/ml anti-ubiquitin mAb (Abcam, Cambridge, MA) and 50 mg/ml donkey serum, and then washed twice with PBS. The cells were stained with Alexa488-conjugated donkey anti-mouse IgG. The slides were mounted and observed using a fluorescence microscope (Olympus FV500, Melville, NY).
xbp1 mRNA splicing assay Total RNA of the treated cells was harvested using TRIzol reagent (Invitrogen). cDNA was synthesized by random hexamers and Superscript III (In vitrogen). The xbp1 mRNA was amplified by using the primers 59-CTG-GAAAGCAAGTGGTAGA-39 and 59-CTGGGTCCTTCTGGGTAGAC-39. PCR fragments of the spliced (XBP1s) and the unspliced xbp1 (XBP1u) were visualized through 2% agarose gels with ethidium bromide staining.
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Apoptosis assay
Target cells treated with S-AGzmK or GzmK, GzmA, or GzmB plus Ad were stained with annexin V-FITC and propidium iodide (PI) for flow cytometry using a FACSCalibur (BD Biosciences, San Jose, CA). The data were analyzed with CellQuest software.
The cyt c release detection
GzmK-treated cells were fractionated with 0.025% digitonin for 5 min on ice. Mitochondrial (pellet) and cytosolic (supernatant) fractions were obtained for cyt c detection by immunoblotting.
Results

VCP associates with GzmK
Previously, we identified several substrates for GzmK, including SET, Ape1, and HMGB2, which also are in the GzmA-associated SET complex (7, 8) . To further investigate other substrates, an inactive GzmK mutant (S-AGzmK) was immobilized with Affi-gel10 resin and passed through HeLa cell lysates for affinity chromatography assay. The S-AGzmK column was eluted with NaCl concentration gradients. After elution with 500 mM NaCl, the eluted fractions were visualized by SDS-PAGE gels and followed by silver staining. The two major bands (97 and 37 kDa) were eluted, as shown in Fig. 1A . The naked resin did not bind to any proteins when washed with .200 mM NaCl . These two bands were cut out and trypsin digested for mass spectrometry analysis. From the peptide fingerprints, 19 experimental masses matched the theoretical masses for VCP with 32.5% protein coverage and 6 matched theoretical masses for SET with 22.02% protein coverage (Fig. 1B) . We provide complete information for the detected peptides for VCP and SET by mass spectrometry (Supplemental Table) . SET was a previously identified substrate for GzmK, thus confirming the reliability of our experimental system. To further examine the direct interaction of VCP with GzmK, rVCP was incubated with S-AGzmK for coimmunoprecipitation assay. The anti-GzmK Ab can precipitate rVCP, and the anti-VCP Ab can also precipitate S-AGzmK (Fig. 1C) . However, Ig employed as control did not pull down either rVCP or S-AGzmK. SAGzmK can coprecipitate with native VCP in HeLa cell lysates ( Fig. 1D ), whereas control Ig had no effect. Therefore, S-AGzmK binds directly to VCP in its recombinant and native forms.
VCP is a substrate of GzmK and cleaved at Arg 713
To test whether VCP is cleaved by GzmK, 1 mM rVCP was incubated with different concentrations of GzmK at 37˚C for 2 h and probed by anti-VCP Ab. VCP began to be degraded at a low concentration of 0.1 mM GzmK ( Fig. 2A) . GzmK processed rVCP in a dose-dependent manner, and rVCP was mostly degraded with 1 mM GzmK. By 10 min, rVCP started to be degraded after 0.5 mM GzmK treatment and GzmK degraded rVCP in a timedependent manner ( Fig. 2A ). Even with a high concentration of 2 mM S-AGzmK, rVCP was uncleaved. Thus, VCP cleavage requires the enzymatic activity of GzmK. The smaller cleaved products were undetectable in the above experiments, even with Coomassie staining (data not shown). The 17-kDa fragment might be further degraded by GzmK. The cleaved product (∼80 kDa) was the N-terminal truncated fragment determined by N-terminal sequencing. We then determined the cleavage site of VCP using site-directed mutagenesis. Because GzmK cleaves its substrate after Arg or Lys, we generated 22 VCP mutations of Arg or Lys to Ala based on the size of the cleavage product. All mutant VCP proteins were expressed and treated with GzmK and visualized by SDS-PAGE, followed by Coomassie staining. We found that only the R713A mutant was resistant to GzmK cleavage (Fig. 2B) , whereas the R700A mutant and others were still cleaved by GzmK (Fig. 2B and data not shown) . Cleavage after arginine is consistent with the tryptase activity of GzmK.
To assess whether GzmK degrades native VCP, HeLa cell lysates (2 3 10 5 cell equivalents) were incubated with different doses of GzmK for 2 h or incubated for different times with 1 mM GzmK. VCP was degraded by GzmK in a dose-and time-dependent manner (Fig. 2C) . The same blot was stripped and reprobed for SET and b-actin. The known GzmK substrate SET was cleaved by GzmK with similar kinetics (Fig. 2C, right panel) . b-actin was unchanged as a good negative control. To further verify that VCP processing is physiologically relevant, HeLa cells were treated with the indicated concentrations of GzmK in the presence of Ad at 37˚C for 6 h. VCP could be cleaved in a dose-dependent manner (Fig. 2D) . The truncated 80-kDa products were undetectable in GzmK-loaded cells, which may be due to its low concentration, instability, or degradation by other factors. b-actin was unchangeable as a good loading control. Similar results were obtained in Jurkat cells (Fig. 2D, right panel) . Furthermore, we found that VCP could be cleaved in a time-dependent manner after loading GzmK (Fig. 2E) . The same blot was stripped and reprobed for SET and b-actin. SET was also processed by GzmK with similar kinetics. Our previous study compared several delivery agents (perforin, Ad, SLO, or protein delivery reagent Pro-Ject) for the GzmK-loading assay (7). We found that utilizing Ad to load GzmK into target cells results in similar dead features and cleavage of its substrates as perforin-delivered GzmK. To confirm whether VCP can be degraded by GzmK with the physiological delivery protein perforin, we loaded GzmK into target HeLa cells with perforin or SLO at 37˚C for 4 h to detect VCP cleavage. Our results indicate that VCP was also cleaved (Fig. 2F) . Additionally, the pan caspase inhibitor z-VAD (100 mM) was preincubated with HeLa cells prior to GzmK loading with Ad. We found that z-VAD did not affect VCP cleavage by GzmK (Fig. 2G) , although the same concentration of z-VAD could completely inhibit GzmBinduced caspase 3 processing of p21 to p19 (Fig. 2H) . However, z-VAD did not affect procaspase 3 processing to p21 by GzmB. bactin was unchangeable as a good loading control. To further determine whether Bid-mediated cyt c release participates in VCP cleavage, Bcl-2 was overexpressed in HeLa cells to examine VCP degradation after GzmK loading (Fig. 2I, left panel) . Compared with the vector-transfected cells, Bcl-2 overexpression could not affect VCP cleavage (Fig. 2I, right panel) . These results indicate that VCP is directly cleaved by GzmK in its recombinant and native forms in cell lysates or GzmK-loaded target cells.
VCP of target tumor cells is degraded in LAK cell-mediated cytolysis
LAK cells can use perforin/Gzm and Fas/Fas ligand pathways to kill target cells. We pretreated HeLa cells with the inhibitor of cytotoxic granule pathway concanamycin A prior to coincubation with LAK cells. concanamycin A could disrupt LAK cell-mediated cytolysis (data not shown). This finding and our previous report indicate that LAK cell-mediated killing is mainly induced by the perforin/Gzm pathway (11) . To further investigate whether VCP is cleaved in cytolysis induced by killer lymphocytes, HeLa cells were incubated with LAK cells at 37˚C for 4 h at different E:T ratios. After incubation with HeLa cells for 4 h, LAK cells were still suspended and removed from the plate wells. Treated HeLa cells were harvested by washing with PBS buffer three times and followed by immunoblotting. VCP in HeLa cells was apparently degraded at the E:T ratios 10:1 and 20:1, just slightly cleaved at the E:T ratio 5:1 (Fig. 3A) ; ∼60-70% HeLa cells at the E:T ratio 20:1 were dead through trypan blue staining. GzmK was expressed in the LAK cells, and anti-GzmK mAb did not react with noncytolytic cells such as 293A cells (Fig. 3B) . We verified that anti-GzmK mAb did not react with other Gzms, only for GzmK (data not shown). We then wanted to examine whether VCP is a physiological substrate for GzmK, so HeLa cell lysates were incubated with all five Gzms (1 mM) at 37˚C for 2 h. Interestingly, VCP was only hydrolyzed by GzmK, not other Gzms (Fig. 3C) . The DNase NM23H1 was unchanged in all the five Gzm-treated HeLa cell lysates. All five Gzms had strong enzymatic activities detected by cleavage of their synthetic substrates (Fig. 3D) : Ac-YRFK-pNA (GzmK), Suc-VANR-pNA (GzmA), Z-IETD-AFC (GzmB), Suc-FLF-pNA (GzmH), and Suc-AAPL-pNA (GzmM). In our experiments, we standardized the enzymatic activities of all Gzms. GzmA could cleave its substrate SET, and GzmB could process procaspase 3 to form active caspase 3, which is in agreement with the above assay (Fig. 3E) . However, VCP was not degraded even after treatment with 1 mM GzmA or GzmB.
The tetrapeptide YRFK includes the most suitable P4-P1 residues to be accommodated by the catalytic pocket of GzmK (24) . Based on our work to discover a GzmM inhibitor (21), the YRFK peptide was acetylated at the N terminus to prevent degradation and linked to CMK in the C terminus to aid in formation of covalent bonds with both the serine and histidine residues of the catalytic triad. The resulting inhibitor, Ac-YRFK-CMK, could block the catalytic activity of GzmK in vitro (data not shown). As shown in Fig. 3F , HeLa cells were preincubated with the GzmK inhibitor prior to GzmK treatment with Ad. The GzmK inhibitor could abolish GzmK-mediated VCP and SET cleavage in a dosedependent manner (left panel). Enzymatic activity was almost lost at an inhibitor/GzmK ratio of 8:1. Similar results were found in LAK-mediated cytolysis (right panel). HeLa cells were preincubated with the GzmK inhibitor (200 mM) before coincubation with LAK cells. The GzmK inhibitor could mostly inhibit VCP cleavage by LAK cells. Taken together, VCP is the physiological substrate for GzmK.
GzmK targets the ERAD complex of target tumor cells
VCP localizes in the cytosol and ER and delivers the ubiquitinated proteins to the cytosolic 26S proteasome for degradation (25) . VCP tightly interacts with polyubiquitinated proteins in the ERAD pathway. This high-affinity binding results from the synergistic binding of VCP and its cofactor Ufd1-Npl4 complex to the polyubiquitin chains (26, 27) . VCP, Ufd1, and Npl4 can form a complex to participate in substrate recognition and degradation (20) . We therefore wanted to test whether GzmK also degrades the other two ERAD complex components, Ufd1 and Npl4. HeLa cell lysates (2 3 10 5 cell equivalents) were incubated with different doses of GzmK for 2 h or incubated for different times with 1 mM GzmK. Ufd1 and Npl4 were degraded by GzmK in a time-and dose-dependent manner (Fig. 4A, 4B ). To further verify that Ufd1 and Npl4 processing is physiologically relevant, HeLa cells were treated with 1 mM GzmK plus Ad at 37˚C for 6 h. These two proteins were cleaved in GzmK-loaded cells (Fig. 4C) . The same blot was stripped and reprobed for b-actin. b-actin was unchanged as a good loading control. Taken together, GzmK is able to target the ERAD complex.
GzmK abolishes the ATPase activity of VCP and accelerates ubiquitinated protein accumulation leading to xbp1 splicing VCP belongs to the AAA family with type II AAA-ATPase activity and regulates many cellular functions. The VCP molecule consists of an N-terminal domain and two ATPase domains named D1 and D2, and these two ATPase domains have different roles in ATPase activity. The D2 domain accounts for the major ATPase activity (15, 28) . Residue Arg 713 in the GzmK cleavage site is located in a disordered loop (705-731) of the D2 domain. This disordered loop will undergo a dramatic structural change to be more ordered during ATP hydrolysis, a process that is of significant importance for the ATPase activity of the D2 domain (29) . We next wanted to detect whether GzmK cleavage interferes with the ability of VCP to hydrolyze ATP. To directly study the ATPase activity, we used a colorimetric assay to measure the Pi release from ATP hydrolysis. Incubation of rVCP with ATP resulted in increasing free phosphates in a dose-dependent manner (Fig. 5A) . Preincubation of rVCP (1.5 mM) with GzmK abolished its ATPase activity in a dose-dependent fashion (Fig. 5B) . A total of 1.5 mM GzmK completely blocked ATPase activity of rVCP, whereas inactive S-AGzmK exhibited no such effect. Ubiquitinated protein accumulation in the ER will increase ER stress and trigger cell death (30, 31) . VCP provides its ATPase activity and forms a complex with the Ufd1-Npl4 heterodimer to take part in the ERAD pathway for misfolded protein degradation (25, 32) . We demonstrated that VCP cleavage by GzmK destroyed its ATPase activity, so we next wanted to assess whether GzmK induces ubiquitinated protein accumulation in target cells. Jurkat cells were treated with buffer, proteasome inhibitor MG132, and 0.5 or 1 mM GzmK plus Ad, respectively, and visualized by immunofluorescence assay with anti-ubiquitin Ab. GzmK caused a dramatic accumulation of intracellular ubiquitinated protein (Fig. 5C ). MG132 was used as a positive control. Similar results were obtained through immunoblotting assay (Fig. 5D) . The antiubiquitin Ab was more sensitive for immunofluorescence staining than Western blot analysis. Additionally, the molecular weights of ubiquitinated proteins were so large, and those proteins were mainly localized on the top of the gel, that it was hard to detect the difference from the gel. Therefore, we quantified these band signals in Fig. 5D by densitometry comparison and marked them. GzmB or GzmA could not significantly induce accumulation of ubiquitinated proteins. These data are representative of at least three separate experiments. Ubiquitinated protein accumulation required GzmK delivery by Ad, as cells treated with either GzmK or Ad alone had no effect. Ad-mediated delivery of the inactive S-AGzmK also had no observable effect (data not shown).
Accumulation of unfolded or misfolded proteins in the ER can initiate the unfolded protein response (UPR) to cause a transcriptional induction pathway for clearing the cytotoxic proteins (33, 34) . These three factors include protein kinase R-like ER kinase, activating transcription factor 6 (ATF6), and inositol-requiring enzyme 1 (IRE1), which are initially induced during the UPR. The transcription factor XBP1 is a target of ATF6, and its mRNA is spliced by IRE1 in response to an ER stress (35) . We examined xbp1 mRNA splicing in GzmK-treated HeLa cells. HeLa cells were treated with 1 mM GzmK plus Ad or 20 mM MG132 for 4 h at 37˚C. xbp1 mRNA was spliced after GzmK treatment (Fig. 5E) . MG132 was used to initiate an ER stress and make xbp1 mRNA splicing to generate a spliced form (XBP1s). xbp1 mRNA could not be processed to maintain a total unspliced form (XBP1u) in the mock-treated cells. GzmB or GzmA could not significantly cause xbp1 splicing. b-actin mRNA was amplified as a control. Together, these results indicate that GzmK can cause ubiquitinated protein accumulation and trigger ER stress in target cells.
VCP silencing facilitates GzmK-mediated cell death
To determine whether VCP cleavage affects GzmK-mediated cell death, we silenced VCP expression in HeLa cells (Fig. 6A) . We designed three shRNA sequences against VCP mRNA sequence and constructed pSUPER-VCP-shRNA plasmids. Three days after transfection, VCP expression was reduced by 70% by one shRNA as shown in Fig. 6A . b-actin was unchanged in either empty vector- (Fig. 6B,  6C) . Mock, GzmK, Ad alone, or S-AGzmK plus Ad induced background death (,10%). The data are representative of at least three separate experiments, as calculated in Fig. 6C (p , 0.01) . Moreover, VCP-silenced HeLa cells completely released cyt c from mitochondria after GzmK loading for 6 h. In contrast, empty vector-transfected cells caused less cyt c release. b-actin and CoxIV were probed for supernatant and pellet controls, respectively. These by 1000 U/ml IL-2 were probed with anti-GzmK Ab. rGzmK was used as a positive control. The 293A cells were used as a negative control. C, VCP is only cleaved by GzmK, not other Gzms. HeLa cell lysates (2 3 10 5 equivalents) were incubated with 1 mM GzmB, GzmH, GzmM, GzmA, or GzmK at 37˚C for 2 h. NM23H1 was probed as a negative control. D, All Gzms have enzymatic activity. The enzymatic activities were detected by cleavage of their synthetic substrates. The relative activity was analyzed by comparing the active Gzms to their solution buffers. Ac-YRFK-pNA (GzmK), Suc-VANR-pNA (GzmA), Z-IETD-AFC (GzmB), Suc-FLFpNA (GzmH), and Suc-AAPL-pNA (GzmM). E, GzmA or GzmB does not cleave the native VCP. HeLa cell lysates (2 3 10 5 equivalents) were incubated with 1 mM GzmA (left panel) or different doses of GzmB (right panel) at 37˚C for 2 h. VCP, caspase 3, SET, b-actin, or NM23H1 was probed by immunoblotting. SET cleavage was used as a positive control, and NM23H1 was used as a negative control for GzmA (left panel). Caspase 3 activation was used as a positive control, and b-actin was used as a negative control for GzmB (right panel). F, The GzmK inhibitor Ac-YRFK-CMK abolishes VCP cleavage in the GzmK-loaded or attacked HeLa cells. HeLa cells were incubated with the different ratios of GzmK inhibitor to GzmK for 1 h before treatment with GzmK (1 mM) plus Ad for 6 h (left panel). VCP and SET were detected by immunoblotting. b-actin was unchanged as a loading control. IL-2-activated LAK cells (the indicated E:T ratios) were coincubated with HeLa cells at 37˚C for 4 h (right panel). For GzmK blocking, HeLa cells were pretreated with 200 mM GzmK inhibitor prior to incubation with IL-2-activated LAK cells. HeLa cells were isolated and probed for VCP by immunoblotting. The same blot was stripped and probed by anti-b-actin Ab. I:K ratio, GzmK inhibitor to GzmK molar ratio. results represent at least three independent experiments. Because VCP is a physiological substrate for GzmK, we next wanted to determine whether VCP silencing affects other Gzm-induced cell death. We found that VCP-silenced HeLa cells were not markedly susceptible to GzmA-or GzmB-induced cell death (Fig. 6E, 6F ). Taken together, VCP silencing is susceptible to GzmK-induced cell death.
VCP overexpression protects cells from GzmK-induced cell death
Because VCP is an important substrate for GzmK, we next wanted to assess whether overexpression of VCP in target cells protects against GzmK-induced cytotoxicity. We overexpressed VCP in target HeLa cells, as shown in Fig. 7A . VCP-overexpressed HeLa cells were treated with 1 mM GzmK plus Ad for 6 h and followed by flow cytometry analysis. GzmK caused 41.9% dead cells in VCP-overexpressed HeLa cells (Fig. 7B) . In contrast, the empty vector-transfected cells resulted in 61.6% dead cells. VCP overexpression was not significantly resistant to GzmA-or GzmBmediated death (Fig. 7C) . Taken together, the results suggest that VCP overexpression is only resistant to GzmK-induced cell death, not GzmA or GzmB.
Discussion
GzmK and GzmA are the only two tryptases among all the five Gzms in humans that are required for NK/CTL-mediated cytotoxicity. Recently, we showed that GzmK induces rapid caspaseindependent cell death with ssDNA nicks (7, 36) . After loading into target cells, GzmK targets the ER-associated SET complex, resulting in the degradation of some important components such as SET, Ape1, and HMGB2. SET cleavage activates the NM23H1 DNase and causes ssDNA nicks. We previously demonstrated that Ape1 can antagonize ROS generation as an antiredox protein (8) . Ape1 cleavage by GzmK abolishes its redox function and triggers ROS accumulation. GzmK can target mitochondria by processing Bid to truncated Bid, leading to release of cyt c and other proapoptotic factors (9, 10) . GzmK also cleaves the tumor suppressor p53 at Lys 24 and Lys 305 to generate three cleavage fragments, which harbor strong proapoptotic activities to sensitize target tumor cells to GzmK-mediated cytotoxicity (11) . To elucidate the mechanisms of GzmK-induced cell death, we further identified other physiological substrates for GzmK by using affinity chromatography. We found that VCP is a physiological substrate for GzmK. GzmK enters the cytoplasm of the target cell and targets the components of the ERAD complex (VCP, Npl4, and Ufd1) to disrupt the ERAD pathway, leading to ER stress (Fig. 7D) . GzmK also degrades SET to release the DNase NM23H1, enabling it to enter the nucleus for DNA nicking. The ER stress and DNA nicking induce the target cell to undergo caspase-independent cell death.
VCP forms a complex with the Ufd1-Npl4 heterodimer that is essential for the ERAD pathway, a process by which constituent and transient ER proteins are removed from the ER and degraded in the cytosolic 26S proteasome (37) . VCP is required to dislocate proteins from the ER to the cytosol in the ERAD pathway. It contains four functional domains, as follows: the N-terminal, D1, D2, and C-terminal domains. The N-terminal domain (aa 1-187) can bind the polyubiquitinated substrates and cofactors (27) . The D1 domain (208-459) mainly stabilizes its conformation. Some studies have shown that mutation in D2 (481-761) significantly inhibits the ATPase activity at physiological temperatures, whereas mutation in the D1 does not. In contrast, mutation in D1, but not D2, impairs the heat-stimulated ATPase activity (28) . DeLaBarre and colleagues (38) demonstrated that some major residues in D2 mediate the VCP activity for the ERAD. The C-terminal domain (761-806) is responsible for membrane fusion and nuclear translocation. Our results showed that GzmK can cleave VCP after Arg 713 , which is localized in the D2 domain that mediates main ATPase activity. VCP cleavage by GzmK at Arg 713 certainly destroys the structural feature near the disordered loop (705-731) and disturbs the conformational changes in this region 5 cell equivalents) were treated with 1 mM GzmK at 37˚C for the indicated times; the reaction was stopped by loading buffer and analyzed using anti-Ufd1 and anti-Npl4 Abs, respectively. The same blot was stripped and reprobed by anti-b-actin Ab. b-actin was unchanged as a negative control. B, GzmK cleaves native Ufd1 and Npl4 in cell lysates in a dose-dependent manner. HeLa cell lysates (2 3 10 5 cell equivalents) were treated with the indicated concentrations of GzmK at 37˚C for 2 h; the cleavage of Ufd1 and Npl4 was tested, as in A. C, GzmK cleaves Ufd1 and Npl4 in cells permeabilized by Ad. HeLa cells were treated with 1 mM GzmK plus Ad for 6 h. The whole-cell lysates were analyzed by immunoblotting. The same blot was stripped and reprobed by anti-b-actin Ab. b-actin was unchanged as a negative control.
supposed to occur during the ATP hydrolysis. Indeed, VCP degradation by GzmK abolishes its ATPase activity.
VCP acts as a molecular chaperon and cooperates with the ubiquitin-proteasome system in mediating misfolded protein degradation. Many newly synthesized proteins are not properly folded and will be ubiquitinated and removed from the ER to the 26S proteasome for degradation. VCP hydrolyzes ATP and provides energy in this process. Abolition of its ATPase function by GzmK dramatically accelerates ubiquitinated protein accumulation. VCP recognizes ubiquitinated substrates and cofactors in the ER. Silenced VCP induces ubiquitinated protein accumulation, leading to xbp1 splicing (data not shown), which is in agreement with pre-FIGURE 5. GzmK disrupts ATPase activity of VCP and accelerates the intracellular ubiquitinated protein accumulation to induce xbp1 mRNA splicing. A, VCP possesses ATPase activity. Different doses of rVCP were incubated with 1 mM ATP for 30 min and analyzed by using Pi release. The Pi release was detected by OD 820 . Each point represents the mean of three independent experiments. B, GzmK abolishes the ATPase activity of VCP. A total of 1.5 mM rVCP was pretreated with the indicated doses of GzmK or inactive S-AGzmK for 1 h prior to adding 1 mM ATP. S-AGzmK was used as a negative control. Each point represents the mean of three independent experiments. C, GzmK induces accumulation of ubiquitinated proteins. The indicated concentrations of GzmK were loaded into Jurkat cells. The levels of intracellular ubiquitinated proteins were analyzed by immunofluorescence microscopy with antiubiquitin Ab. The proteasome inhibitor MG132 was used as a positive control. D, Similar results were obtained by immunoblotting assay. GzmA or GzmB does not induce accumulation of ubiquitinated proteins. HeLa cells were incubated with 1 mM GzmK, GzmA, or GzmB plus Ad, respectively, before probing for the ubiquitin and b-actin. The numbers represent the ratio of ubiquitin to b-actin signal by densitometry compared with the mock-treated cells. The mock-treated cells were normalized to 1. E, GzmK, not GzmA or GzmB, induces xbp1 mRNA splicing. HeLa cells were treated with 1 mM GzmK, GzmA, or GzmB plus Ad for 4 h, or 20 mM MG132 for 4 h as a control. Total RNA was isolated from the treated target HeLa cells, and xbp1 mRNA splicing was analyzed by PCR. Unspliced (XBP1u) and spliced (XBP1s) forms were shown in the figure. b-actin mRNA was amplified as a control.
vious reports (32, 39) . Accumulation of unfolded or misfolded proteins in the ER can initiate the UPR to cause a transcriptional induction pathway for clearing the cytotoxic proteins (33, 34) . In this study, we found that GzmK can rapidly enter into the cytosol after being introduced into target cells (data not shown). GzmK can target VCP and the ERAD complex to abolish its biological functions. Moreover, GzmK can cleave the other two ERAD complex components, Ufd1 and Npl4. Cleavage of Ufd1 and Npl4 will further disrupt the ERAD pathway for ubiquitinated protein degradation and accelerate an ER stress. The transcription factor XBP1 is a target of ATF6, and its mRNA is spliced by IRE1 in rersponse to an ER stress (35) . xbp1 mRNA splicing is dramatically induced after GzmK treatment. It implies an ER stress appears in GzmK-treated tumor cells. VCP-silenced and control HeLa cells were treated with 1 mM GzmK plus Ad at 37˚C for 6 h. Supernatant and pellet fractions were separated for cyt c detection by immunoblotting. The supernatant b-actin or pellet COXIV was probed as a control. These data are representative of at least three separate experiments. E and F, VCP silencing does not affect GzmA-or GzmB-mediated cell death. VCP-silenced HeLa cells were treated with 1 mM GzmA plus Ad (E) or the indicated concentrations of GzmB plus Ad at 37˚C for 4 h (F) and followed by flow cytometry. Total dead cells were calculated by annexin V and PI singlepositive as well as annexin V/PI double-positive cells shown as means 6 SD (right panels). Supern, supernatant. Previously, we demonstrated that GzmK induced a rapid generation of ROS and collapse of mitochondrial inner membrane potential (8, 9) . GzmK trafficking in the target cells needs further investigation via three-dimensional methodology. GzmK cleaves the antioxidant protein Ape1 to facilitate ROS accumulation in target cells (8) . Accumulating evidence suggests that protein folding and production of ROS are closely linked events (40) . The ER is an organelle in which proper folding and disulfide formation of proteins are dependent on the redox status within the lumen of the ER. ROS generation will destroy the redox status in the ER and promote unfolded and misfolded protein accumulation and increase an ER stress. In contrast, an ER stress may elicit Ca 2+ leakage into the cytosol and increase ROS generation in mitochondria. This cross-talk will initiate caspase-independent cell death.
